<DOC>
	<DOC>NCT02462928</DOC>
	<brief_summary>This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration.</brief_summary>
	<brief_title>A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Diagnosis of agerelated macular degeneration in at least 1 eye Best corrected visual acuity of 20/40 to 20/320 in the study eye Best corrected visual acuity of 20/200 or better in the nonstudy eye History of vitrectomy, macular surgery, or glaucoma surgery in the study eye Cataract or refractive surgery in the study eye within the last 3 months</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>